Drug Trial Radar · NCT06343779
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Feb 26, 2024
Primary completion
Oct 17, 2025
Study completion Oct 17, 2025
Sponsor
- Lead sponsor
- Pharvaris Netherlands B.V.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.
Conditions
- Hereditary Angioedema
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
- Hereditary Angioedema Types I and II
- Hereditary Angioedema Attack
- Hereditary Angioedema With C1 Esterase Inhibitor Deficiency
- Hereditary Angioedema - Type 1
- Hereditary Angioedema - Type 2
- C1 Esterase Inhibitor [C1-INH] Deficiency
- C1 Esterase Inhibitor Deficiency
- C1 Esterase Inhibitor, Deficiency of
- C1 Inhibitor Deficiency
- Hereditary Angioedema - Type 3
- Hereditary Angioedema Type III
Interventions
Deucrictibant, PlaceboDrug
Deucrictibant Soft Capsules for Oral Use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment.Time frame: Pre-treatment to 12 hours post-treatment.
Locations
76 sites in 29 countries. Site status is shown where the registry gives one.
Study Site
Birmingham, Alabama
Study Site
Paradise Valley, Arizona
Study Site
Little Rock, Arkansas
Study Site
San Diego, California
Study Site
Santa Monica, California
Study Site
Walnut Creek, California
Study Site
Colorado Springs, Colorado
Study Site
Chevy Chase, Maryland
Study Site
Boston, Massachusetts
Study Site
Detroit, Michigan
Study Site
St Louis, Missouri
Study Site
Hershey, Pennsylvania
Study Site
Dallas, Texas
Study Site
Buenos Aires, Argentina
Study Site
Salta, Argentina
Study Site
Box Hill, Australia
Study Site
Campbelltown, New South Wales, Australia
Study Site
Graz, Austria
Study Site
Linz, Austria
Study Site
Vienna, Austria
Study Site
Paraná, Brazil
Study Site
Ribeirão Preto, Brazil
Study Site
Salvador, Brazil
Study Site
Santo André, Brazil
Study Site
São Paulo, Brazil
Study Site
Sofia, Bulgaria
Study Site
Sofia, Bulgaria
Study Site
Edmonton, Alberta, Canada
Study Site
Bogotá, Colombia
Study Site
Bogotá, Colombia
Study Site
Bogotá, Colombia
Study Site
Medellín, Colombia
Study Site
Brno, Czechia
Study Site
Lille, France
Study Site
Paris, France
Study Site
Berlin, Germany
Study Site
Frankfurt am Main, Germany
Study Site
Frankfurt am Main, Germany
Study Site
Lübeck, Germany
Study Site
Hong Kong, Hong Kong
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.